REHOVOT, Israel, Nov. 02, 2016 -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the third quarter of 2016 on Monday, November 21, 2016.
On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.
A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-254-7270 toll free from the United States, or +972-3-925-5937 internationally. The replay will be accessible through November 23, 2016, and an archive of the webcast will be available on the Company’s website through December 2, 2016.
About Evogene Ltd.:
Evogene (NYSE:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at [email protected].
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Karen Mazor, Director Investor Relations E: [email protected] T: +972 54 228 2039


Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



